The Plecanatide Chronic Idiopathic Constipation (CIC) Study

This study has been completed.
Sponsor:
Collaborator:
PAREXEL International
Information provided by (Responsible Party):
Synergy Pharmaceuticals Inc.
ClinicalTrials.gov Identifier:
NCT01429987
First received: September 6, 2011
Last updated: May 28, 2013
Last verified: May 2013

September 6, 2011
May 28, 2013
October 2011
December 2012   (final data collection date for primary outcome measure)
Complete Spontaneous Bowel Movement (CSBM) [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
A complete spontaneous bowel movement occurs 24 hours away from laxative use and the patient reports a feeling of complete evacuation. A weekly responder will have 3 or more CSBMs and an increase of at least one CSBM from baseline. A monthly responder achieves this for 3 of the 4 weeks in a month. An overall responder must achieve this in 2 of the 3 months of treatment with one of those months being the latest treatment period.
Complete Spontaneous Bowel Movement (CSBM) [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
To detect at least a 10% difference in Overall Complete Spontaneous Bowel Movement (CSBM) responders between each dose of plecanatide and placebo. A complete spontaneous bowel movement occurs 24 hours away from laxative use and the patient reports a feeling of complete evacuation. A weekly responder will have 3 or more CSBMs and an increase of at least one CSBM from baseline. A monthly responder achieves this for 3 of the 4 weeks in a month. An overall responder must achieve this in 2 of the 3 months of treatment with one of those months being the latest treatment period.
Complete list of historical versions of study NCT01429987 on ClinicalTrials.gov Archive Site
Reduction in straining and abdominal symptoms such as pain, discomfort and bloating. [ Time Frame: 12 Weeks ] [ Designated as safety issue: No ]
To demonstrate the reduction in straining and abdominal symptoms such as pain, discomfort and bloating as determined via patient reported outcome (PRO) measures collected via an Interactive Voice Response System (IVRS). To demonstrate an improvement in the hardness of stool , the frequency of spontaneous movements, and a reduction in time to first bowel movement. To monitor and report all treatment emergent adverse events.
Same as current
Not Provided
Not Provided
 
The Plecanatide Chronic Idiopathic Constipation (CIC) Study
Study SP304-20210: A Randomized, 12-Week, Double-Blind, Placebo-Controlled, Repeat-Dose, Oral, Dose-Ranging Study to Assess the Safety and Efficacy of Plecanatide in Patients With Chronic Idiopathic Constipation

This is a randomized, double-blind, placebo controlled, 12 week repeat oral dose, dose ranging study to determine the efficacy and safety of 3 doses of plecanatide compared to placebo in patients with Chronic Idiopathic Constipation (CIC).

This is a Phase IIb/III, randomized, double-blind, placebo-controlled, 12-Week, Repeat, Oral Dose Ranging, study to determine the safety and efficacy of plecanatide in patients with chronic idiopathic constipation (CIC). Subjects diagnosed with CIC via modified Rome III criteria will be screened against the inclusion and exclusion criteria for the study and enter a 2 Week pre treatment screening. During this phase patients will be required to call in their bowel movements (BM diary) as they occur, and call at least once daily to complete a patient diary of questions on their symptoms (Symptom Diary) associated with CC, as they will throughout the trial. Patients who complete at least 5 days of dosing per week, 6 of each 7 day period of BM diary calls, and continue to have less than 3 complete spontaneous movements per week (as well as meeting other inclusion and exclusion criteria) will be enrolled and randomized to one of three plecanatide doses 0.3 mg, 1.0 mg, and 3.0 mg or placebo. 880 patients will be randomized with the intent of having 200 patients per treatment group (each group the same size) included in efficacy analyses. All subjects receiving at least one dose of plecanatide or matching placebo will be included in the safety analyses.

Interventional
Phase 2
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Chronic Idiopathic Constipation
Drug: plecanatide
Subjects receive experimental study drug for 12 weeks.
  • Experimental: plecanatide 0.3 mg
    Subjects receive plecanatide 0.3 mg for 12 consecutive weeks
    Intervention: Drug: plecanatide
  • Experimental: plecanatide 1.0 mg
    Subjects receive plecanatide 1.0 mg for 12 consecutive weeks
    Intervention: Drug: plecanatide
  • Experimental: plecanatide 3.0 mg
    Subjects receive plecanatide 3.0 mg for 12 consecutive weeks
    Intervention: Drug: plecanatide
  • Experimental: Placebo
    Subjects receive placebo for 12 consecutive weeks
    Intervention: Drug: plecanatide
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
951
December 2012
December 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female aged 18-75, inclusive
  • Body Mass Index = 18-35 kg/m2, inclusive
  • Meets modified Rome III criteria for functional chronic idiopathic constipation for at least 3 months with symptom onset for at least 6 months. Note: For this trial, patients with manual maneuvers required for >25% of defecations will not be eligible for participation.
  • Less than 3 CSBMs per week at baseline and during pretreatment
  • Completed a colonoscopy in accordance with medical guidelines as appropriate, with no clinically significant findings
  • Patient is willing to discontinue use of supplemental fiber, laxatives, prescription and nonprescription medications, herbal or dietary supplements intended to treat constipation during the screening, pre-treatment, treatment and 2-week post-treatment periods
  • Willing to maintain a stable diet during the study.
  • Patients with hemorrhoids and/or diverticulosis (NOT diverticulitis) CAN be entered into the study.

Exclusion Criteria:

  • Loose stool (mushy) or watery (Bristol score- 6 or 7) stool in the absence of any laxative or prohibited medicine for > 25% of BMs during the 3 months prior to screening visit OR during the 14 day treatment period
  • Patient meets the Rome III criteria for Irritable Bowel Syndrome (IBS-C)
  • Active peptic ulcer disease not adequately treated or not stable
  • History of cathartic colon, laxative, enema abuse, or ischemic colitis.
  • Fecal impaction within 3 months of screening
  • Patient has had /has any: diseases or conditions associated with constipation (GI or CNS), structural abnormality of the GI tract or gastric bypass surgery, pelvic floor dysfunction, pseudo-obstruction, active infectious gastritis, diverticulitis, anal fissures or any disease or condition that can affect GI motility or defecation or can be associated with abdominal pain
  • Unexplained and clinically significant "alarm symptoms" including lower GI bleeding, iron-deficiency anemia, weight loss or systemic signs of infection or colitis.
  • Major surgery within 60 days of screening.
Both
18 Years to 75 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01429987
SP304-20210, SP-SP30420210
No
Synergy Pharmaceuticals Inc.
Synergy Pharmaceuticals Inc.
PAREXEL International
Not Provided
Synergy Pharmaceuticals Inc.
May 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP